NCT01591655

Mapracorat Ophthalmic Suspension, 3% for the Treatment of Ocular Inflammation and Pain Following Cataract Surgery

The Efficacy and Safety of Mapracorat Ophthalmic Suspension, 3% in Subjects for the Treatment of Ocular Inflammation and Pain Following Cataract Surgery.

• Status: Completed
• Phase: Phase 3
• Study type: Interventional
• Enrollment: 360 (actual)
• Sponsor: Bausch & Lomb Incorporated · Industry
• Sex: All
• Age: 18 Years
• Healthy volunteers: Not accepted

Summary

The objective of this clinical study is to compare the safety and efficacy of mapracorat ophthalmic suspension, 3% with its vehicle for the treatment of postoperative inflammation and pain following cataract surgery. Participants from the United States and Canada will be recruited for this study.

Conditions

• Cataract
• Inflammation
• Surgery

Interventions

Type	Name	Description
DRUG	Mapracorat	1 drop of study medication into the study eye four times daily (QID) for 14 days
DRUG	Vehicle	1 drop of vehicle into the study eye QID for 14 days.

Timeline

• Start date: 2012-07-01
• Primary completion: 2013-09-01
• Completion: 2013-10-01
• First posted: 2012-05-04
• Last updated: 2020-09-03
• Results posted: 2020-09-03

Locations

1 site across 1 country: United States